Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A140 vs Erbitux plus mFOLFOX6 in first-line RAS wild-type metastatic colorectal cancer
CTR20202451Phase 3Completed
- Sponsor
- Kelun-Biotech
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of KL-140 in colorectal adenocarcinoma, sponsored by Kelun-Biotech. Started Dec 2020; status: completed.
02
Drugs
KL-140
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20202451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202451.